Profitelligence Profitelligence · Filing Ledger Open IQV research →

Form 8-K · Current Report · Filed 2026-05-05

IQVIA Reports Strong Q1 2026 Financial Results and Raises Guidance

IQVIA Holdings Inc. reported strong financial results for the first quarter of 2026, with revenue of $4.151 billion, up 8.4% year-over-year. The company's GAAP net income was $274 million, and adjusted EBITDA was $932 million. IQVIA also raised its full-year 2026 guidance for adjusted diluted earnings per share to a range of $12.65 to $12.95. Additionally, the company repurchased $552 million of its common stock during the quarter.

Filer
Iqvia Holdings Inc. IQV · NYSE
Filed
Accession
0001628280-26-030118
CIK
0001478242
Signal
High impactHealthcare

Items reported

Item events

Reported Item

Earnings Beat General Statement Share Repurchase Program Announced Raised Guidance

Market reaction

Close before filing

$160.94

Next session

+9.6%

Since filing

+46.0%

Latest close

$235.02

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from IQV reporting the same item, with the next session's move:

Insider tape

Within 45 days of this filing, IQV insiders reported 4 Form 4 transactions — net buying of $143K.

Full IQV insider history →

About Iqvia Holdings Inc.

Iqvia Holdings Inc. is a leading global provider of advanced analytics, technology solutions, and contract research services. Its primary function is to support the healthcare sector by offering data-driven insights and innovations that underpin strategic decision-making across pharmaceutical, biotechnology, and medical device industries. Iqvia plays a crucial role in facilitating drug development through its comprehensive clinical research capabilities, encompassing everything from clinical trials to regulatory submissions. Additionally, its technology solutions leverage artificial intelligence and machine learning to optimize clinical and commercial operations, contributing to enhanced patient outcomes and streamlined healthcare delivery. Iqvia's integrated services impact sectors such as drug safety, patient engagement, and real-world evidence, making it an indispensable partner for healthcare companies seeking to navigate complex markets and regulatory environments. Globally recognized for its vast data repository and cutting-edge analytical platforms, Iqvia serves as a pivotal player in the transformation of the healthcare landscape, empowering organizations to accelerate innovation and improve patient care.

Exchange NYSE Industry Diagnostics & Research Company website ↗

Never miss another IQV filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts